Ultime notizie per US Physical Therapy (NYSE:USPH) Azioni

US Physical Therapy

US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

CECO

ESTC

USPH

Gli insider acquistano azioni chiave: scopri i dettagli degli investimenti milionari su Elastic, US Physical Therapy e altre società.

Questi insider puntano su 4 azioni chiave: ecco su cosa investono

US Physical Therapy Inc

Barrington Research analyst Michael Petusky maintains US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Outperform and maintains $108 price target.

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on US Physical Therapy, Maintains $108 Price Target

U.S. Physical Therapy, Inc. (&quot;USPH&quot;) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced that it has signed an agreement to purchase a 50% equity interest in a management services organization (the &quot;Company&quot;) that provides management and administrative services to 50 physical therapy clinics. The Company expects to close the transaction on October 31, 2024.
The Company manages 50 outpatient clinics, the majority of which are in New York, with plans to further expand in New York and adjacent states. The Company-managed clinics deliver physical, occupational and speech therapy and also provide physical therapy services to patients in their homes. Through its managed therapy providers, the Company currently generates approximately $64.0 million in annual revenue and approximately $12.0 million in annual EBITDA on a consolidated basis. The current owners of the Company will continue to have a 50% ownership interest. The Chief Executive Officer of the Company, who will remain with the Company as its executive leader, joined the Company in 2016 and has grown the group of managed clinics from five clinics to 50 clinics.

U.S. Physical Therapy Announces That It Has Signed An Agreement To Purchase A 50% Equity Interest In A Management Services Organization That Provides Management And Administrative Services To 50 Physical Therapy Clinics; No Financial Terms Disclosed

Wall Street started the week in the red, as traders weighed the economic and geopolitical fallout from escalating tensions in the Middle East. 
Monday marked the one-year anniversary of Hamas&#8217; October 7 attack, which triggered the <a href="https://www.benzinga.com/etfs/specialty-etfs/24/10/41210761/oil-surges-on-1-year-hamas-attack-anniversary-as-israel-mulls-iran-retaliation">ongoing war in Gaza</a>. The situation is now threatening to spread across the region, as Israel considers retaliating for last week&#8217;s missile attacks from Iran.
By 1 p.m. ET, the major indices were modestly lower, with the S&amp;P 500 down 0.5% and the Dow Jones off by 0.7%. The Nasdaq 100 also slid 0.5%. The energy sector was the only bright spot, buoyed by surging oil prices.
West Texas Intermediate (WTI) crude, as tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), jumped over 3%, climbing to $77 per barrel. This rally marked its fifth consecutive session of gains, fueled by concerns that Israel may retaliate against Iran, a key oil producer, for its involvement in regional conflicts.
Last week&#8217;s blowout U.S. labor market data, coupled with rising oil prices and fresh stimulus measures out of China, pushed 10-year Treasury yields above 4%, setting the stage for the highest levels since late July. Investors appear increasingly wary of long-duration bonds, sending the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) down 0.6%, extending its losing streak to four sessions.
Market sentiment around the Federal Reserve&#8217;s upcoming policy decisions has also shifted. The probability of the Fed refraining from cutting interest rates next month has dropped to just 17%, according to CME FedWatch Tool, 
Rising yields weighed heavily on metals, with gold down 0.4% to $2,645 per ounce and silver dropping 1.3%. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) gained 1.4%, trading at $63,682. 
<h1 class="wp-block-heading">Monday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,724.31</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,930.58</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,059.07</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,191.35</td>
<td>-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:30 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent100724&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;edged down 0.5% to $570.38.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.7% to $420.90.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.5% to $485.21.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) tumbled 0.8% to $218.77.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 0.8%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.7%.</li>
</ul>
<h1 class="wp-block-heading">Monday&#8217;s Stock Movers</h1>
<ul>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) rallied 14% after the company announced it is currently shipping more than 100,000 graphics processors per quarter and unveiled a new suite of liquid cooling products.</li>
<li>Everest Group Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) plummeted over 8% after Morgan Stanley lowered its price target on the stock from $450 to $430.</li>
<li>Constellation Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) fell nearly 2% after Bank of America downgraded the stock from Outperform to Neutral and lowered the price target from $300 to $255. </li>
<li>Bank of America also downgraded several healthcare stocks including Concentra Group Holding Parent Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>), down 4.6%; AMN Healthcare Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>), down 1.9%; Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>), down 6% and U.S. Physical Therapy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), down 2.5%.</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41207490/s-p-500-could-reach-6-300-in-12-months-says-goldman-sachs-driven-by-strong-ai-demand-and-margin-">S&amp;P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By &#8216;Strong AI Demand&#8217; And &#8216;Margin Expansion&#8217;</a></li>
</ul>
Image was created using artificial intelligence.

Equities

Broad U.S. Equity ETFs

Commodities

Global

Econ #s

Federal Reserve

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

SMCI

iShares Trust Barclays 20+ Year Treasury Bond Fund

XLRE

Stocks Fall As Oil Prices Spike, 10-Year Yields Top 4%, Energy Sector Outperforms: What's Driving Markets Monday?

B of A Securities analyst Joanna Gajuk downgrades US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) from Buy to Neutral and lowers the price target from $114 to $90.

Downgrades

B of A Securities Downgrades US Physical Therapy to Neutral, Lowers Price Target to $90

Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Elastic</h3>
<ul>
<li>The Trade: Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) Director Paul R. Auvil III acquired a total of 20,000 shares at  an average price of $74.25. To acquire these shares, it cost around $1.48 million.</li>
<li>What's Happening: On Aug. 29, Elastic reported quarterly earnings of 35 cents per share, which beat the analyst consensus estimate of 25 cents per share.</li>
<li>What Elastic Does: Elastic is a software company based in Mountain View, California, focusing on search-adjacent products.</li>
</ul>
<h3 class="wp-block-heading">U.S. Physical Therapy</h3>
<ul>
<li>The Trade: U.S. Physical Therapy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) Director Kathleen A Gilmartin acquired a total of 2,000 shares at an average price of $86.09. To acquire these shares, it cost around $172,180.</li>
<li>What's Happening: On Aug. 13, US Physical Therapy posted downbeat quarterly earnings.</li>
<li>What U.S. Physical Therapy Does: US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.</li>
</ul>
<h3 class="wp-block-heading">CECO Environmental</h3>
<ul>
<li>The Trade: CECO Environmental Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) Director Richard F Wallman <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 10,000 shares</a> at an average price of $28.77. To acquire these shares, it cost around $1.98 million. The company's President and CEO also bought $287,722 shares.</li>
<li>What's Happening: On July 30, CECO Environmental reported worse-than-expected second-quarter revenue results and raised its FY24 revenue guidance above estimates.</li>
<li>What CECO Environmental Does: CECO Environmental Corp serves the energy, industrial, and other niche markets.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/09/40700380/dollar-tree-dicks-sporting-goods-and-3-stocks-to-watch-heading-into-wednesday">Dollar Tree, Dick&#8217;s Sporting Goods And 3 Stocks To Watch He</a><a href="https://www.benzinga.com/24/09/40700380/dollar-tree-dicks-sporting-goods-and-3-stocks-to-watch-heading-into-wednesday">ading Into Wednesday</a></li>
</ul>

$1.5M Bet On Elastic? Check Out These 4 Stocks Executives Are Buying

The Company acquired a&nbsp;70%&nbsp;interest in the Company with the current owners retaining a&nbsp;30%&nbsp;ownership interest.

U.S. Physical Therapy Acquires A Physical Therapy And Hand Therapy Practice With Eight Clinic Locations In Pennsylvania Which Currently Generates ~$5.5M In Annual Revenues

Graham Reeve, COO at US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), reported an insider sell on August 21, according to a new SEC filing. 
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000885978/000095017024099579//Archives/edgar/data/885978/000095017024099579/0000950170-24-099579-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, Reeve sold 1,724 shares of US Physical Therapy. The total transaction value is $142,230.
At Thursday morning, US Physical Therapy shares are down by 0.0%, trading at $83.11.
<h3>Delving into US Physical Therapy's Background</h3>
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
<h3>A Deep Dive into US Physical Therapy's Financials</h3>
Revenue Growth: US Physical Therapy's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 10.37%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 20.25%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): US Physical Therapy's EPS is below the industry average. The company faced challenges with a current EPS of 0.47. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: US Physical Therapy's debt-to-equity ratio is below the industry average. With a ratio of 0.53, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 83.95, US Physical Therapy's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 1.99, US Physical Therapy's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 19.93, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000885978">Check Out The Full List Of US Physical Therapy's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COO Of US Physical Therapy Makes $142K Sale

Concentra Group Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>) priced in July its initial public offering of 22.5 million shares <a href="https://www.benzinga.com/pressreleases/24/07/n39947510/select-medical-holdings-corporation-announces-pricing-of-concentra-group-holdings-parent-inc-initi" target="_blank" rel="noreferrer noopener">at $23.50 per share</a>.
RBC Capital Markets initiated coverage of Concentra, citing a &#8220;differentiated operating and reimbursement model with strong growth.&#8221;
RBC Capital analyst Ben Hendrix wrote Concentra offers a unique investment strategy with minimal exposure to regulatory and payor negotiation challenges faced by other providers, as its revenue mainly comes from employers and workers compensation rather than government or managed care reimbursements.
&#8220;We see upside to Concentra&#8217;s post-IPO trading levels based on the company&#8217;s dominant market position as the country&#8217;s leading occupational healthcare provider,&#8221; RBC Capital noted.
The analyst initiated with an Outperform rating and a price target of $33.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40446983/concentras-high-quality-business-model-attracts-analyst-attention-initiates-with-bu" target="_blank" rel="noreferrer noopener">Concentra&#8217;s High-Quality Business Model Attracts Analyst Attention, Initiates With Buy Rating</a>.
Since the IPO, Concentra&#8217;s trading performance has closely mirrored that of its parent company, Select Medical Holdings Corp.&#8217;s subsidiary (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>).
RBC Capital wrote that this valuation is too low for an independent entity with stronger profit margins and a more favorable reimbursement profile than Medicare-reimbursed post-acute care providers.
Although Concentra lacks direct public peers, RBC Capital analyst sees high-margin outpatient operators focused on musculoskeletal cases, such as Surgery Partners Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) and U.S. Physical Therapy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), as suitable comparisons.
Given Concentra&#8217;s more favorable reimbursement structure, the analyst expects its valuation to approach the 14.0x target as management executes its expansion plans and taps into a robust pipeline of growth opportunities.
Concentra provides occupational and consumer health services and other direct-to-employer care to more than 50,000 patients each day on average from 547 occupational health centers in 41 states and 154 onsite health clinics.
The company has 11,000 employees.
CON Price Action: Concentra Group Holdings stock is down 0.73% at $23.18 at publication Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/08/40467815/arbitration-to-uncover-hidden-value-of-hess-guyana-oil-assets-in-exxon-mobil-vs-chevron-dispute-" target="_blank" rel="noreferrer noopener">Arbitration To Uncover Hidden Value Of Hess&#8217; Guyana Oil Assets In Exxon Mobil vs. Chevron Dispute: Report</a>.</li>
</ul>
Photo: This Is Engineering via Upsplash

Analyst Color

Health Care

Initiation

Movers

General

SGRY

Concentra's Post-IPO Trading Levels Based On 'Its Dominant Market Position,' Says Analyst

Barrington Research analyst Michael Petusky maintains US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Outperform and lowers the price target from $122 to $108.

Barrington Research Maintains Outperform on US Physical Therapy, Lowers Price Target to $108

Guidance

U.S. Physical Therapy Returned Its Guidance For Adjusted EBITDA For 2024 To Its Original Range Of $80M-$85M

US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) reported quarterly earnings of $0.73 per share which missed the analyst consensus estimate of $0.82 by 10.98 percent. This is a 3.95 percent decrease over earnings of $0.76 per share from the same period last year. The company reported quarterly sales of $167.19 million which beat the analyst consensus estimate of $162.35 million by 2.98 percent. This is a 10.37 percent increase over sales of $151.49 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

US Physical Therapy Q2 Adj $0.73 Misses $0.82 Estimate, Sales $167.19M Beat $162.35M Estimate

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Amedisys (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amed#NASDAQ">AMED</a>) or U.S. Physical Therapy (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usph#NYSE">USPH</a>). But which of these two stocks is more attractive to value investors? We&#39;ll need to take a closer look to find out.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Amedisys has a Zacks Rank of #2 (Buy), while U.S. Physical Therapy has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that AMED likely has seen a stronger improvement to its earnings outlook than USPH has recently. But this is just one factor that value investors are interested in.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
AMED currently has a forward P/E ratio of 21.14, while USPH has a forward P/E of 34.11. We also note that AMED has a PEG ratio of 2.37. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company&#39;s expected earnings growth rate. USPH currently has a PEG ratio of 3.77.
Another notable valuation metric for AMED is its P/B ratio of 2.80. The P/B ratio is used to compare a stock&#39;s market value with its book value, which is defined as total assets minus total liabilities. For comparison, USPH has a P/B of 3.04.
These are just a few of the metrics contributing to AMED&#39;s Value grade of B and USPH&#39;s Value grade of C.
AMED is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that AMED is likely the superior value option right now.
<a href="https://www.zacks.com/stock/news/2310183/amed-vs-usph-which-stock-is-the-better-value-option?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-2310183">To read this article on Zacks.com click here.</a>

Small Cap

AMED

AMED vs. USPH: Which Stock Is the Better Value Option?

Barrington Research analyst Michael Petusky maintains US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Outperform and maintains $122 price target.

Barrington Research Maintains Outperform on US Physical Therapy, Maintains $122 Price Target

U.S. Physical Therapy Sees 2024 Adj. EBITDA $82.5M-$87.5M

US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) reported quarterly earnings of $0.51 per share which missed the analyst consensus estimate of $0.56 by 8.93 percent. This is a 13.56 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $155.675 million which beat the analyst consensus estimate of $153.366 million by 1.51 percent. This is a 4.83 percent increase over sales of $148.509 million the same period last year.

US Physical Therapy Q1 2024 Adj EPS $0.51 Misses $0.56 Estimate, Sales $155.675M Beat $153.366M Estimate

U.S. Physical Therapy Announces Acquisition Of An IIP Services Business By Briotix Health Limited Partnership For Purchase Price Of ~$24M

U.S. Physical Therapy, Inc. (&quot;USPH&quot; or the &quot;Company&quot;) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced the acquisition of a physical therapy and hand therapy practice with nine clinic locations.
USPH acquired a&nbsp;50%&nbsp;equity interest in the practice for a purchase price of&nbsp;$16.4 million, with the current practice owners retaining a&nbsp;50%&nbsp;interest. The business currently generates approximately&nbsp;$11.4 million&nbsp;in annual revenues and approximately 65,000 annual visits.

US Physical Therapy Announces Acquisition of a 50% Stake in Nine-Clinic Physical Therapy And Hand Therapy Practice for $16.4M

Revealing a significant insider sell on March 14, Carey Hendrickson, Chief Financial Officer at US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), as per the latest SEC filing.
What Happened: After conducting a thorough analysis, Hendrickson sold 1,800 shares of US Physical Therapy. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000885978/000095017024031674//Archives/edgar/data/885978/000095017024031674/0000950170-24-031674-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total transaction value is $193,103.
US Physical Therapy's shares are actively trading at $106.55, experiencing a down of 0.0% during Friday's morning session.
<h3>Unveiling the Story Behind US Physical Therapy</h3>
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
<h3>Understanding the Numbers: US Physical Therapy's Finances</h3>
Revenue Growth: Over the 3 months period, US Physical Therapy showcased positive performance, achieving a revenue growth rate of 9.65% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 19.71%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): US Physical Therapy's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.38.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.54.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: US Physical Therapy's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 83.24.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 2.5 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 23.01, US Physical Therapy demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Transaction Codes To Focus On</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000885978">Check Out The Full List Of US Physical Therapy's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chief Financial Officer Of US Physical Therapy Makes $193K Sale

JP Morgan analyst Calvin Sternick maintains US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Overweight and raises the price target from $99 to $117.

JP Morgan Maintains Overweight on US Physical Therapy, Raises Price Target to $117

An update from US Physical Therapy (USPH) is now available. U.S. Physical Therapy recently conducted a conference call and webcast to discuss their...

US Physical Therapy Q2 and H1 2024 Financial Overview

US Physical Therapy (USPH) has provided an announcement. U.S. Physical Therapy, Inc., a leading national operator of outpatient physical therapy cl...

US Physical Therapy CEO to Present at Midwest IDEAS Conference

U.S. Physical Therapy announces the aquisition of an eight-clinic practice

In a report released today, Michael Petusky from Barrington maintained a Buy rating on US Physical Therapy (USPH – Research Report), with a price t...

Buy Rating Affirmed for U.S. Physical Therapy Amid Strong Demand and Strategic Cost Management

Morgan Stanley identifies 39 stocks likely to face tax loss selling pressure

Select Medical Holdings: No Reason To Downgrade This One Just Yet

Morgan Stanley's list of tax loss selling stocks

U.S. Physical Therapy acquires 50% equity interest in a clinic management organization

US Physical Therapy ( ($USPH) ) has provided an announcement. U.S. Physical Therapy, Inc. has announced the acquisition of a 50% stake in a managem...

US Physical Therapy Expands Empire with Strategic Acquisition

Barrington analyst Michael Petusky maintained a Buy rating on US Physical Therapy (USPH – Research Report) today and set a price target of $108.00....

Buy Rating on U.S. Physical Therapy, Inc. Affirmed After Strategic MSO Metro Acquisition

ACHC

ADBE

APTV

ARCH

BIIB

BKDT

CHRD

CIVI

DVAX

IIIN

IRDM

NBIX

NVEE

PLAB

PRGO

PRVA

PTEN

RGEN

ROCK

SMPL

SPTM

TALO

XPEL

Press Releases

U.S. Physical Therapy Reports First Quarter 2024 Results

U.S. Physical Therapy to Present at the Bank of America Securities Healthcare Conference 2024

U.S. Physical Therapy to Present at the Jefferies Global Healthcare Conference 2024

U.S. Physical Therapy to Present at the 14th Annual East Coast IDEAS Conference 2024

U.S. Physical Therapy to Present at the CJS Securities 24th Annual New Ideas Summer Conference

U.S. Physical Therapy, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call

U.S. Physical Therapy Reports Second Quarter 2024 Results

U.S. Physical Therapy to Present at the 15th Annual Midwest IDEAS Investor Conference

U.S. Physical Therapy Announces the Acquisition of an Eight-Clinic Physical Therapy Practice

U.S. Physical Therapy Announces Acquisition of 50-Clinic Physical Therapy Management Services Organization

Barrington Research

B of A Securities

JP Morgan

U.S. Physical Therapy

Comments

US Physical Therapy

Notizie

Ultime notizie per US Physical Therapy (NYSE:USPH) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO